Weekly review of information from the medicine and biotech market


Krka: The general meeting decided to allocate EUR 204.4 million from the 2022 net profit of EUR 408.2 million to dividends, which means a payment of EUR 6.6 per share, the company announced.

Krka: Recorded EUR 170.1 million of consolidated net profit in H1 2023 vs. EUR 236.2 million profit a year earlier, the company announced, presenting estimated data.

Molecure: Received a declaration from its largest shareholder, Black Forest SICAV-SIF (holding 29.69%), regarding the will to participate in the public offering of new issue series H shares, the company announced.

Molecure: It has started the book-building process as part of an offering of no more than 2,776,000 H-series shares based on approved authorized capital, the company announced. The book-building for series H shares will last until July 11, 2023, and the issue price will be determined no later than July 12, 2023.

Celon Pharma: Dorota Zwolińska resigned from the position of a member of the management board of Celon Pharma and financial director for personal reasons as of July 4, 2023, the company announced. At the same time, she informed that the supervisory board adopted a resolution to appoint, as of July 4, this year. Bartosz Szałek became a member of the management board, entrusting him with the function of a member of the management board and financial director. Bartosz Szałek has been cooperating with private equity funds for over 15 years, supervising the finances of portfolio companies.

Polfa Tarchomin: Polish Security Printing Works (PWPW) will buy land from Polfa Tarchomin on which it wants to build a modern securities factory within the next few years. In turn, Polfa Tarchomin will gain an additional PLN 143 million thanks to this transaction, which will be allocated to Polfa Tarchomin completing the construction of the Center for the Development and Production of Oncological Drugs. The entire project will cost around PLN 550 million, the Ministry of State Assets (MAP) announced.

Selvita: It conducts intensive sales activities among biotechnology and pharmaceutical companies and expects that the strategy will have a positive impact on the company’s sales in key markets, Miłosz Gruca, Vice President and Chief Commercial Officer of the company, informed ISBnews. At the same time, it is working on the development of its drug discovery offer.

Bayer: Christian Sarto has been appointed head of Bayer’s Consumer Health division in the CEE region. Laércio Bortolini became the head of Bayer’s Crop Science division for Poland, the Czech Republic, Slovakia and the Baltic States, retaining the current position of head in Ukraine. Both managers have been managing teams of several hundred people from Warsaw since July this year.

Medicalgorithmics: The artificial intelligence system created by Medicalgorithmics can diagnose the risk of a dangerous type of cardiac arrhythmia of ventricular tachycardia before the first clinical symptoms appear in patients, the company said as part of the summary of a two-year research project. The conclusions were presented in the periodical “Heart Rhythm O2”.

Ryvu Therapeutics: It has concluded two agreements with Zakłady Farmaceutyczne Polpharma in the area of production of the active substance (API) of the drug RVU120 for the purposes of phase II clinical trials, the company announced. The agreements are important elements of the implementation of Ryvu’s development plans for 2022-2024. The total value of both contracts will amount to approx. EUR 1.7 million.

Synektik: Positively completed consultations with the US Food and Drug Administration (FDA) as part of the Pre-IND meeting procedure, the company announced. The consultations were aimed at obtaining confirmation of the proposed strategy for the development of a cardiotracer molecule intended for PET-CT myocardial perfusion studies by accepting the main assumptions of the phase III clinical trial protocol in the United States.

Molecure: concluded with Orion Sante Sarl based in France (Simbec-Orion) an agreement for the organization and comprehensive conduct of a Phase II Proof-of-Concept clinical trial to determine the clinical efficacy, pharmacokinetics, pharmacodynamics and safety of the OATD-01 chitinase inhibitor in patients with active pulmonary sarcoidosis, the company said. The value of the contract is approx. EUR 10.1 million, which is the equivalent of approx. PLN 45 million.

Medinice: Received from the European Patent Office confirmation of patent protection for the Pacepress invention. This is the second European patent for this project obtained in connection with the expansion of its functionality, the company said. The aim of the project is to create an automated compression dressing, the aim of which is to reduce the risk of hematoma in the bed after implantation of devices used in cardiac electrotherapy, e.g. pacemaker or cardioverter.


Our privacy policy